Heart Disease Journals

Cardiology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gatzoulis MA et al. – Uncontrolled studies suggest that prostacyclin analogues and phosphodiesterase type–5 inhibitors may have benefits in advanced pulmonary vascular disease. In the only randomised controlled trial dedicated to end–stage PAH–CHD, bosentan significantly reduced pulmonary vascular resistance and significantly increased 6–minute walk distance without compromising peripheral oxygen saturation, in patients with Eisenmenger syndrome. These data suggest that targeted therapies are beneficial in the PAH–CHD population, and warrant further research.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address